Work

Regadenoson, An Adenosine 2A Receptor Agonist, Is Safe and Inhibits Invariant NKT Cells in Sickle Cell Disease

Year: 2011

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v118.21.849.849

Authors: Joshua Field, Gene Lin, Maureen Okam, Elaine Majerus, Onyinye Onyekwere, Ainsley Ross, Donna Neuberg, Federico Campigotto, David G. Nathan, Joel Linden

Institutions: Versiti Blood Center of Wisconsin, La Jolla Institute for Immunology, Brigham and Women's Hospital, Harvard University, Washington University in St. Louis, Howard University, Dana-Farber Cancer Institute

Language: English

Topic: Hemoglobinopathies and Related Disorders

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2587073729

FWCI:

Cites:

Cited by:

Related to: 10